Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ47156 Monotherapy and Combination Therapy in Advanced Malignant Solid Tumors
NCT06571422Phase 1Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of WJ47156 in advanced malignant solid tumor (3 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 1 year, Adverse Events at 2.5 years and 3 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
WJ47156
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT06571422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571422.